MANCHESTER, Conn., Feb. 22, 2013 (GLOBE NEWSWIRE) -- Charter Medical, Ltd., a Lydall subsidiary, (NYSE:LDL) announced today that it has established a strategic partnership with CELLution Biotech B.V., an innovative developer and provider of bioreactors and fermenters based in the Netherlands. By combining their respective expertise in single-use technology and mass transfer, the partnership will provide customers in North America and Europe with turnkey single-use solutions for fermentation and perfusion cell growth.
Charter Medical To Be The Exclusive Distributor For CELLution Biotech In North America And The European Union
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.